These data also suggest that effective ADAM12 and CYP1B1 loss leads to a remarkable attenuation of RCC tumorigenic potential in vivo and functionally validates our model of a reciprocal regulation of CAAs and RCC in kidney cancer. This evidence concerns the gene ADAM12 and renal cell carcinoma.